文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

无既往耐药突变HIV感染者接受BIC/FTC/TAF或DTG/3TC治疗的真实世界病毒学失败与耐药发生研究

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

这项单中心回顾性研究纳入1059例无既往NRTI或InSTI耐药突变的HIV感染者,比较BIC/FTC/TAF与DTG/3TC方案的病毒学失败和耐药发生。总体病毒学失败率7.5%,耐药发生仅0.9%,InSTI耐药在BIC/FTC/TAF和DTG/3TC组分别为0.17%和0.65%,支持这两类基于InSTI方案的稳健性。

要点

  • 无既往耐药突变者使用BIC/FTC/TAF或DTG/3TC,病毒学失败率分别为9.8%和4.5%。
  • 总体耐药发生仅0.9%,InSTI耐药在BIC/FTC/TAF组0.17%、DTG/3TC组0.65%。
  • 真实世界中两类InSTI方案耐药风险低,支持其稳健性。

核心结论

  • 在无既往NRTI或InSTI耐药突变的HIV感染者中,BIC/FTC/TAF或DTG/3TC治疗期间InSTI耐药发生罕见,支持方案稳健性。

研究设计与样本

  • 回顾性单中心研究,纳入2018年1月至2025年1月间接受BIC/FTC/TAF或DTG/3TC且无既往NRTI或InSTI耐药突变、随访至少6个月的HIV感染者,共1059例。

主要发现

  • 总体病毒学失败79/1059(7.5%),BIC/FTC/TAF组9.8%,DTG/3TC组4.5%。
  • 总体Blip 96/1059(9.0%),BIC/FTC/TAF组9.9%,DTG/3TC组5.8%。
  • 耐药发生9例(0.9%),BIC/FTC/TAF组4例(其中InSTI耐药突变1/4),DTG/3TC组5例(其中InSTI耐药突变3/5)。

关键数值与推荐

  • 病毒学失败定义为确认HIV RNA >50 copies/mL或单次HIV RNA >200 copies/mL后更改治疗。
  • Blip定义为单次HIV RNA在50-200 copies/mL之间。
  • 上述阈值应用于一线治疗超过6个月后,或病毒学抑制维持治疗中任何时间点。
  • 耐药判读采用ANRS算法V35。

临床怎么用

  • 对于无既往耐药突变的HIV感染者,BIC/FTC/TAF和DTG/3TC均为耐药风险低的稳健选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate, in a large real-world cohort of people living with HIV (PLWH) treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir/lamivudine, rates of virological failure (VF) and resistance emergence. METHODS: All PLWH receiving BIC/FTC/TAF or dolutegravir/lamivudine without prior NRTI or integrase strand transfer inhibitor (InSTI) resistance-associated mutations (RAMs) and with at least 6 month follow-up between January 2018 and January 2025 were included in this retrospective single-centre study. Demographic, therapeutic and immunovirological data were collected from electronic medical records. VF was defined as confirmed HIV RNA >50 copies/mL or a single HIV RNA >200 copies/mL followed by modification of treatment. Blip was defined as a single HIV RNA between 50 and 200 copies/mL. These thresholds were applied after >6 months of first-line therapy (FLT), or at any timepoint in virological suppression maintenance therapy (MT). Plasma HIV genotyping by Sanger sequencing was performed at the clinician's request, and resistance was interpreted using the ANRS algorithm V35. RESULTS: A total of 1059 PLWH were included: 594 receiving BIC/FTC/TAF (141 FLT and 453 MT) and 465 receiving dolutegravir/lamivudine (23 FLT and 442 MT). VF occurred in 79/1059 PLWH (7.5% overall; 9.8% in the BIC/FTC/TAF group and 4.5% in the dolutegravir/lamivudine group) and blips in 96/1059 PLWH (9.0% overall; 9.9% and 5.8%, respectively, groupwise). Resistance emergence was documented in nine cases (0.9%), four for BIC/FTC/TAF (InSTI-RAM in 1/4) and five for dolutegravir/lamivudine (InSTI-RAM in 3/5). CONCLUSIONS: In this real-world cohort, InSTI resistance emergence in PLWH failing BIC/FTC/TAF or dolutegravir/lamivudine was rare at 0.17% and 0.65%, respectively, supporting the robustness of these InSTI-based regimens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Drumel T, Kimmerlin J, Allavena C, et al. Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study. J Antimicrob Chemother. 2026. PMID: 42455039. doi:10.1093/jac/dkag247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。